Eli Lilly (LLY) Moves Fast to Secure Lead in India’s Obesity Drug Market
Eli Lilly and Company (NYSE:LLY) is moving quickly to lock in its position in India’s fast-growing obesity drug market.
Eli Lilly & Co (LLY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 4,453,062 | $3,397,687,594 | +4% | 1.23% |
| 2. | 2,327,200 | $1,775,653,600 | -38% | 0.27% | |
| 3. | 2,229,400 | $1,701,032,200 | +30% | 0.26% | |
| 4. | Citadel Investment Group Ken Griffin | 1,152,818 | $879,600,134 | +36% | 0.13% |
| 5. | Adage Capital Management Phill Gross And Robert Atchinson | 806,866 | $615,638,758 | -5% | 0.98% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $691.79 | 715 | $494,626.99 | 14,685 | 2025-08-15 | Filing | |
| $660.25 | 758 | $500,472.53 | 758 | 2025-08-13 | Filing | |
| $647.36 | 1,000 | $647,360.00 | 20,562 | 2025-08-13 | Filing | |
| $644.77 | 1,632 | $1,052,263.01 | 546,601 | 2025-08-12 | Filing | |
| $634.41 | 1,000 | $634,405.00 | 137,660 | 2025-08-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1,085.04 | 3,593 | $3,898,530.76 | 92,190,516 | 2025-12-29 | Filing | |
| $1,085.17 | 2,629 | $2,852,919.82 | 92,194,109 | 2025-12-24 | Filing | |
| $1,085.04 | 240 | $260,409.12 | 92,196,738 | 2025-12-23 | Filing | |
| $1,110.53 | 1,340 | $1,488,106.18 | 92,196,978 | 2025-11-25 | Filing | |
| $1,109.45 | 9,249 | $10,261,293.80 | 92,198,318 | 2025-11-25 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 95,492,993 | $72,861,153,659 | 100% | |
| 2. | 80,959,089 | $61,771,784,907 | 0.92% | |
| 3. | 65,809,763 | $50,212,850,031 | 0.88% | |
| 4. | 51,347,232 | $39,177,938,016 | 23.76% | |
| 5. | 34,726,558 | $26,496,363,754 | 0.92% |
News See All
14 Best Pharma Dividend Stocks to Buy in 2026
For most drugmakers, the US is the largest single market. Prices there are often close to three times higher than in other developed countries. Branded medicines carry even steeper premiums.
Jim Cramer Answered Questions About These 11 Stocks
“What really mattered today, though, is the possibility that funding for the data center build-out, something that was beginning to seem chimerical, has tantalizingly returned to a degree of certainty...
Jim Cramer Discusses Major Catalyst For Eli Lilly (LLY)
Eli Lilly and Company (NYSE:LLY) is another top Cramer healthcare stock.
BofA Maintains Buy on Eli Lilly (LLY), Expects 2027 Earnings to Fully Realize Value of Obesity Drug Launches
Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy in 2026.
Eli Lilly and Company (LLY) Announces Updated Meaningful Data on Breast Cancer Treatment
Eli Lilly and Company (NYSE:LLY) is one of the best forever stocks to buy according to hedge funds.
8 Stocks on Jim Cramer's Radar
In a recent appearance on CNBC's Squawk on the Street, Jim Cramer discussed the current climate surrounding AI spending and data center buildout.
14 Best Forever Stocks to Buy According to Hedge Funds
A sky-high valuation is a significant concern heading into 2026. After two years of blockbuster gains, most stocks are trading above historical norms.
10 Best Growth Stocks to Buy in 2026
On December 10, Meghan Shue, Wilmington Trust chief investment strategist, appeared on CNBC's 'The Exchange'.
Eli Lilly and Company (LLY) Releases Updated Results from Phase 3 EMBER-3 Study of Inluriyo (imlunestrant)
Eli Lilly and Company (NYSE:LLY) is one of the Best Stocks to Invest in for the Next 3 Years.
Hedge Fund Resource Center Billionaire Hedge Funds
